Avilar Therapeutics Increases Financing to $75 Million to Advance Pipeline of Novel Extracellular Protein Degraders
New investors Sanofi Ventures, Medical Excellence Capital, and Astellas Venture Management join syndicate with founder RA Capital Management Funding supports advancing multiple first-in-class degrader pipeline programs for the treatment of autoimmune...